Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

By Charmi Patel

June 20, 2024

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to various debilitating symptoms. The economic burden of MS is significant, with Disease-modifying drugs (DMDs) constituting a major portion of healthcare costs. The cost-effectiveness and cost-utility of DMDs for relapsing-remitting multiple sclerosis (RRMS) is the focus of this systematic study.

Key Findings

First-Line Treatments: Studies reveal the cost-effectiveness of various DMDs such as dimethyl fumarate, natalizumab, ozanimod, interferon beta-1a, ocrelizumab, ofatumumab, and teriflunomide. These medications show incremental cost-effectiveness ratios (ICERs) ranging from $13,110/QALY to $48,000/QALY, offering improved outcomes and higher Quality-Adjusted Life Years (QALYs) for RRMS patients.

Second-Line Treatments: Noteworthy findings include the cost-effectiveness of ofatumumab and alemtuzumab, with ICERs of $24,189/QALY and $32,000/QALY, respectively. These treatments demonstrate superior outcomes and higher QALYs compared to other DMDs. Ocrelizumab emerges as a beneficial treatment option for RRMS patients, with an ICER of $166,338/QALY.

Third-Line Treatments: Studies on highly active RRMS (HDA) patients indicate the cost-effectiveness of cladribine tablets over alemtuzumab, fingolimod, and natalizumab, with ICERs ranging from $20,000/QALY to $40,000/QALY. Cladribine tablets are identified as a dominant and cost-effective treatment for HDA patients.

DMDs in Highly Active RRMS Patients: Natalizumab is highlighted as a cost-effective treatment choice for highly active RRMS patients, offering improved outcomes and higher QALYs with an ICER of $30,000/QALY compared to other DMDs.

DMDs in Secondary Progressive MS (SPMS): Siponimod is identified as a cost-effective treatment option for SPMS patients, providing greater QALYs and Years of Life (YLs) with an ICER of $25,000/QALY compared to other DMDs.

Rituximab Analysis: Studies on rituximab reveal lower costs and higher QALYs in MS patients compared to natalizumab, with an ICER of $35,000/QALY. Rituximab emerges as a promising treatment option for MS management.

Conclusion

The review points out how crucial it is to treat RRMS with DMDs that are both helpful and affordable. Cladribine tablets, natalizumab, alemtuzumab, and siponimod emerged as optimal choices for different subsets of MS patients. Oral DMDs were favoured over injectable and intravenous options due to their convenience and cost-effectiveness. Care-oriented strategies like Best Supportive Care (BSC) and Symptom Management (SM) were recommended over drug-focused approaches for RRMS treatment.

Recommendations

Healthcare policymakers, neurologists, and stakeholders should consider the local context and cost-effectiveness data when making decisions about MS treatment strategies. Further research is needed to explore the long-term effectiveness and cost implications of different DMDs across diverse healthcare settings.

Reference url

Recent Posts

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.